CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

18.47 CAD
+0.31 (+1.71%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • CPH had positive earnings in the past year.
  • In the past year CPH had a positive cash flow from operations.
  • Each year in the past 5 years CPH has been profitable.
  • CPH had a positive operating cash flow in each of the past 5 years.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 17.46%, CPH belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
  • CPH's Return On Equity of 21.65% is amongst the best of the industry. CPH outperforms 90.32% of its industry peers.
  • CPH's Return On Invested Capital of 9.24% is amongst the best of the industry. CPH outperforms 90.32% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 9.14%.
  • The last Return On Invested Capital (9.24%) for CPH is above the 3 year average (7.38%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 17.46%
ROE 21.65%
ROIC 9.24%
ROA(3y)16.09%
ROA(5y)19.87%
ROE(3y)19.41%
ROE(5y)23.95%
ROIC(3y)7.38%
ROIC(5y)11.67%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

1.3 Margins

  • CPH has a Profit Margin of 54.17%. This is amongst the best in the industry. CPH outperforms 100.00% of its industry peers.
  • In the last couple of years the Profit Margin of CPH has grown nicely.
  • The Operating Margin of CPH (33.43%) is better than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of CPH has declined.
  • CPH's Gross Margin of 80.12% is amongst the best of the industry. CPH outperforms 96.77% of its industry peers.
  • CPH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.43%
PM (TTM) 54.17%
GM 80.12%
OM growth 3Y-14.47%
OM growth 5Y-9.91%
PM growth 3Y-25.08%
PM growth 5Y20.8%
GM growth 3Y-0.22%
GM growth 5Y-1.37%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CPH.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
  • Compared to 1 year ago, CPH has less shares outstanding
  • Compared to 5 years ago, CPH has less shares outstanding
  • CPH has a better debt/assets ratio than last year.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • CPH has an Altman-Z score of 8.36. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 8.36, CPH belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
  • The Debt to FCF ratio of CPH is 0.19, which is an excellent value as it means it would take CPH, only 0.19 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.19, CPH belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
  • CPH has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.04, CPH is doing good in the industry, outperforming 74.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.19
Altman-Z 8.36
ROIC/WACC1.07
WACC8.65%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.12 indicates that CPH should not have too much problems paying its short term obligations.
  • CPH has a worse Current ratio (1.12) than 80.65% of its industry peers.
  • A Quick Ratio of 0.79 indicates that CPH may have some problems paying its short term obligations.
  • CPH has a Quick ratio of 0.79. This is in the lower half of the industry: CPH underperforms 70.97% of its industry peers.
  • CPH does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.79
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CPH.CA Growth Analysis

3.1 Past

  • CPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 126.09%, which is quite impressive.
  • CPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 43.65% yearly.
  • CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 51.22%.
  • The Revenue has been growing by 18.48% on average over the past years. This is quite good.
EPS 1Y (TTM)126.09%
EPS 3Y0.69%
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)51.22%
Revenue growth 3Y34.62%
Revenue growth 5Y18.48%
Sales Q2Q%3.35%

3.2 Future

  • CPH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.30% yearly.
  • The Revenue is expected to grow by 11.81% on average over the next years. This is quite good.
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.01, the valuation of CPH can be described as correct.
  • 77.42% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
  • CPH is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 17.94, the valuation of CPH can be described as rather expensive.
  • CPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 64.52% of the companies in the same industry.
  • CPH is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.29, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.01
Fwd PE 17.94
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
  • Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than 74.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.56
EV/EBITDA 14.08
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The excellent profitability rating of CPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • No dividends for CPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (4/24/2026, 7:00:00 PM)

18.47

+0.31 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.97%
Ins Owner ChangeN/A
Market Cap466.92M
Revenue(TTM)50.45M
Net Income(TTM)27.33M
Analysts77.5
Price Target19.92 (7.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)146.06%
Min EPS beat(2)66.34%
Max EPS beat(2)225.78%
EPS beat(4)3
Avg EPS beat(4)80.27%
Min EPS beat(4)-7.18%
Max EPS beat(4)225.78%
EPS beat(8)5
Avg EPS beat(8)36.37%
EPS beat(12)9
Avg EPS beat(12)70.11%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.19%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)-2.37%
Revenue beat(4)1
Avg Revenue beat(4)-1.64%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)0.41%
Revenue beat(12)3
Avg Revenue beat(12)2.5%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)1.74%
PT rev (3m)1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.5%
EPS NY rev (1m)25.21%
EPS NY rev (3m)91.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.72%
Revenue NY rev (1m)2.01%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE 13.01
Fwd PE 17.94
P/S 6.76
P/FCF 11.56
P/OCF 11.48
P/B 2.7
P/tB 9.28
EV/EBITDA 14.08
EPS(TTM)1.42
EY7.69%
EPS(NY)1.03
Fwd EY5.57%
FCF(TTM)1.6
FCFY8.65%
OCF(TTM)1.61
OCFY8.71%
SpS2.73
BVpS6.83
TBVpS1.99
PEG (NY)N/A
PEG (5Y)0.3
Graham Number14.7744 (-20.01%)
Profitability
Industry RankSector Rank
ROA 17.46%
ROE 21.65%
ROCE 12.83%
ROIC 9.24%
ROICexc 9.8%
ROICexgc 35.19%
OM 33.43%
PM (TTM) 54.17%
GM 80.12%
FCFM 58.52%
ROA(3y)16.09%
ROA(5y)19.87%
ROE(3y)19.41%
ROE(5y)23.95%
ROIC(3y)7.38%
ROIC(5y)11.67%
ROICexc(3y)10.65%
ROICexc(5y)20.81%
ROICexgc(3y)28.57%
ROICexgc(5y)N/A
ROCE(3y)10.25%
ROCE(5y)16.21%
ROICexgc growth 3Y-8.89%
ROICexgc growth 5Y-26.34%
ROICexc growth 3Y-24.04%
ROICexc growth 5Y-22.32%
OM growth 3Y-14.47%
OM growth 5Y-9.91%
PM growth 3Y-25.08%
PM growth 5Y20.8%
GM growth 3Y-0.22%
GM growth 5Y-1.37%
F-Score8
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.19
Debt/EBITDA 0.22
Cap/Depr 2.78%
Cap/Sales 0.4%
Interest Coverage 250
Cash Conversion 123.36%
Profit Quality 108.04%
Current Ratio 1.12
Quick Ratio 0.79
Altman-Z 8.36
F-Score8
WACC8.65%
ROIC/WACC1.07
Cap/Depr(3y)669.05%
Cap/Depr(5y)403.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3Y0.69%
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue 1Y (TTM)51.22%
Revenue growth 3Y34.62%
Revenue growth 5Y18.48%
Sales Q2Q%3.35%
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A
EBIT growth 1Y114.98%
EBIT growth 3Y15.14%
EBIT growth 5Y6.74%
EBIT Next Year66.86%
EBIT Next 3Y28.71%
EBIT Next 5YN/A
FCF growth 1Y148.8%
FCF growth 3Y41.15%
FCF growth 5Y21.99%
OCF growth 1Y52.08%
OCF growth 3Y41.11%
OCF growth 5Y20.52%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.


Can you provide the valuation status for CIPHER PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for CIPHER PHARMACEUTICALS INC?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.


What is the earnings growth outlook for CIPHER PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to decline by -27.65% in the next year.